SSGJ-705 is under clinical development by 3SBio and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SSGJ-705’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SSGJ-705 is under development for the treatment of HER2 positive solid tumors including breast cancer and gastric cancer. The drug candidate is a recombinant bi-specific monoclonal antibody which acts by targeting PD1 and HER2. The drug candidate is administered through intravenous and parenteral route in the form of lyophilized powder.
3SBio is a biotechnology company that discovers, develops, manufactures, and markets biopharmaceutical products. The company develops recombinant or genetically engineered, protein-based products and other pharmaceutical product candidates to meet significant unmet medical needs in the areas of cancer and its supportive care, nephrology, dermatology, and other disease conditions. The company distributes its products to hospitals, clinics, and dialysis centers in China. The company sells its products in Colombia, Brazil, Costa Rica, Egypt, Dominican Republic, Guatemala, El Salvador, Mongolia, Laos, Pakistan, Sri Lanka, Myanmar, the Philippines, Paraguay, Thailand, and Trinidad and Tobago. 3SBio is headquartered in Shenyang, Liaoning, China.
For a complete picture of SSGJ-705’s drug-specific PTSR and LoA scores, buy the report here.